Keum J. Yang
Daejeon St. Mary's Hospital
Daejeon, Republic of Korea
Daejeon, Republic of Korea
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
The differential expression of EPHB4 and ephrin B2 in cutaneous squamous cell carcinoma according to the grade of tumor differentiation: a clinicopathological study.
Journal: International journal of dermatology
Published: July 28, 2020
Cilastatin Preconditioning Attenuates Renal Ischemia-Reperfusion Injury via Hypoxia Inducible Factor-1α Activation.
Journal: International journal of molecular sciences
Published: April 17, 2020
Corrigendum to "Paricalcitol Pretreatment Attenuates Renal Ischemia-Reperfusion Injury via Prostaglandin E2 Receptor EP4 Pathway".
Journal: Oxidative medicine and cellular longevity
Published: June 06, 2017
Cilastatin attenuates vancomycin-induced nephrotoxicity via P-glycoprotein.
Journal: Toxicology letters
Published: December 29, 2016
Paricalcitol attenuates lipopolysaccharide-induced inflammation and apoptosis in proximal tubular cells through the prostaglandin E2 receptor EP4.
Journal: Kidney research and clinical practice
Published: December 08, 2016
Paricalcitol Pretreatment Attenuates Renal Ischemia-Reperfusion Injury via Prostaglandin E2 Receptor EP4 Pathway.
Journal: Oxidative medicine and cellular longevity
Published: December 04, 2016
Genetic screen identifies suppressor of morphogenesis in genitalia-1 (SMG-1) as a modulator of sorafenib resistance in hepatocellular carcinoma cell lines.
Journal: International journal of oncology
Published: August 05, 2013
Pretreatment with paricalcitol attenuates inflammation in ischemia-reperfusion injury via the up-regulation of cyclooxygenase-2 and prostaglandin E2.
Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Published: December 12, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026